[go: up one dir, main page]

WO1993000807A1 - Procede de stabilisation de biomateriaux - Google Patents

Procede de stabilisation de biomateriaux Download PDF

Info

Publication number
WO1993000807A1
WO1993000807A1 PCT/US1992/005643 US9205643W WO9300807A1 WO 1993000807 A1 WO1993000807 A1 WO 1993000807A1 US 9205643 W US9205643 W US 9205643W WO 9300807 A1 WO9300807 A1 WO 9300807A1
Authority
WO
WIPO (PCT)
Prior art keywords
drying
protein
freezing
group
biomaterial
Prior art date
Application number
PCT/US1992/005643
Other languages
English (en)
Inventor
John F. Carpenter
Original Assignee
Cryolife, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cryolife, Inc. filed Critical Cryolife, Inc.
Publication of WO1993000807A1 publication Critical patent/WO1993000807A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Definitions

  • the invention described herein relates to a method of stabilizing biomaterials, especially labile proteins, during drying or freeze-drying using stabilizing components to achieve enhanced protection.
  • Freeze-drying processes have been used with limited degrees of success in protein preservation due to protein denaturation and/or inactivation caused by the freezing or sublimation steps. Even under conditions where the freezing phase of the process is not damaging (i.e., the protein can withstand freezing stress or a cryoprotectant is used) , the subsequent removal of water from the sample by sublimation of the frozen sample (drying phase) can lead to irreversible damage.
  • additives are also used to improve the stability of the protein during long- term storage of the dried product.
  • proteins are inherently stable against acute freeze-drying stress, and only need to be protected during the subsequent storage of the dried product.
  • Human growth hormone and ribonuclease A are examples of this type of protein.
  • the current invention relates to a method of employing solutes which stabilize labile proteins and other biomaterials during the acute stresses encountered during freeze- drying. Additionally, the compositions of the present invention enhance overall protein recovery after freeze- drying and storage of the dried product. The solute mixture that confers stability against acute stresses during freeze-drying also aids in long-term storage of the protein or other biomaterial.
  • Damage to freeze-dried proteins is manifested after rehydration, for example, as a loss of protein solubility, aggregation upon rehydration, loss of activity in appropriate bioassays (e.g., stimulated or depressed mitosis or activity of cells induced by growth factors, or antigen binding by an antibody) or in the case of enzymes, a loss of catalytic activity.
  • bioassays e.g., stimulated or depressed mitosis or activity of cells induced by growth factors, or antigen binding by an antibody
  • enzymes e.g., a loss of catalytic activity.
  • the latter parameter is an extremely sensitive measure of protein damage.
  • An enzyme that is fully soluble and has not aggregated may still display a loss of catalytic activity if it has undergone damaging conformational changes.
  • assays for characterizing catalytic activity are straightforward and are not subjected to the variability and vagaries of bioassays, such as those employed for hormones and growth factors.
  • enzymes are ideal model systems for studies on the stabilization of proteins during freeze drying.
  • One object of the present invention is to provide a method of stabilizing proteins against both the freezing and drying stresses encountered during lyophilization, preferably by employing a two-component system. Whereas component one or two when used alone may not provide adequate protection of the protein both during freezing and drying, when these components are used in combination, protection during freezing and drying is obtained. Thus with embodiments of this method, synergistic protection of the protein can be realized during freeze-drying, with component one providing primary stabilization against freezing and component two primarily protecting during the drying phase.
  • One advantage of the present invention is to obtain freeze- drying stabilization by employing solutes that would not normally be expected to protect labile proteins during freeze-drying.
  • An object of the present invention is to speed and simplify development of freeze-drying protocols for the stabilization of labile proteins.
  • An improved method for stabilizing biomaterials, especially labile proteins, during freeze- drying is disclosed, wherein stabilization is realized employing an additive system, preferably a two-component system.
  • one component may serve as a cryoprotectant to protect the protein against damage due to freezing, while conferring minimal protection during the subsequent drying phase.
  • Component two may be selected and employed to confer minimal protection during freezing, and when used alone affords no protection or is damaging to the protein during drying.
  • DETAILED DESCRIPTION Freeze-drying involves lyophilization and refers to the process by which an aqueous solution of a protein and additives is frozen, after which the water is removed by sublimation at low pressure. Subsequent rehydration of the dried protein preparation is typically necessary to use the protein and to assay the effect of the processing steps on protein activity.
  • the drying phase typically involves all stages of the sublimation process following freezing.
  • Excipients and stabilizing solutes or additives are compounds that are added to the protein solution or suspension (broadly referred to herein as a "protein solution") prior to freeze-drying to improve the stability of the protein to the freeze-drying cycle, and to improve the storage stability of the dried product.
  • the invention described herein relates to a method of employing preferably a two-component mixture of solutes to stabilize labile proteins against the stresses encountered by freeze-drying.
  • the method also aids in overall protein recovery after freeze-drying and storage of the dried product. That is, the solutes that confer stability against acute stresses also aid in the long-term storage of the protein.
  • Component one, used to stabilize the protein comprises a polymer which provides at least some cryoprotection for the protein.
  • the cryoprotectant is preferably a compound that has the capacity to protect the protein during freezing and subsequent thawing or during the freezing phase of a freeze-drying process. Some cryoprotectants also protect during the subsequent drying step of freeze-drying.
  • Preferred examples of polymers that can serve as cryoprotectants for proteins include: polyethylene glycol, polyvinyl pyrrolidone, hydroxyethyl starch, dextran and ficoll.
  • the polymers used herein can include compounds having a molecular weight of greater than about 500 daltons.
  • Polyethylene glycol is a preferred polymer useful as component one because it is commonly used during protein purification and thus it often present in solution with a protein to be freeze-dried. Polyethylene glycol is useful in that t prevents the protein from sticking to the surface of the container in which it is present. A preferred level of polyethylene glycol is from about 0.5 to about 20%(w/v) of the suspension.
  • Component two is a compound that when used alone may provide minimal if any protection for the protein during either freezing or drying, and may actually potentiate the protein damage when used alone. Examples of compounds that can be used as component two include:
  • sugars e.g., trehalose, lactose, sucrose, glucose, galactose, maltose, mannose and fructose
  • polyhydroxy alcohols e.g., mannitol, sorbitol and inositol
  • amino acids e.g., glycine, alanine, proline and lysine
  • methylamines e.g., trimethylamine-N- oxide, betaine and sarcosine.
  • Some compounds suitable for use as the second component protect freeze-dried proteins under certain conditions, such as at specific initial concentrations (e.g., the influence of trehalose on freeze-dried phosphofructokinase; Carpenter and Crowe, Biochemistry 28:3916-3922, 1989), whereas others appear to be virtually ineffective at protecting labile proteins during freeze-drying (e.g., the influence of glycine on freeze-dried phosphofructokinase; Carpenter et al., Biochem, Biophys. Acta, 923: 109-115, 1987) .
  • component two protects the protein during the drying phase of the freeze-drying process.
  • a preferred level is from about 1 to about 300 mM.
  • freeze-drying stabilization is not limited to sugars.
  • Compounds such as polyhydroxy alcohols, amino acids and methylamines are surprisingly effective at stabiLizing proteins during the drying phase.
  • component one can be comprised of one or more of the cryoprotectant solutes defined above.
  • component two can be comprised of one or mo:-e of the above defined solutes.
  • the invention described herein can also be used to stabilize other biological materials such as viruses or human, animal, or bacterial cells during freeze drying.
  • proteins such as a growth factors, hormones, antibodies, antigens, enzymes, clotting factors, structural proteins and complement factors can be combined with components one and two as described herein and subjected to freeze- drying. Specifically, such proteins would include:
  • CAMPATH-1, anti-TAC, etc. Polyclonal antibodies; Human IgM; and Human IgG.
  • a labile biomaterial such as a liposome, cell organelle, vaccine, virus, bacteria, eukaryotic cell, platelet, living-cell viral vaccine, other subcellular element, genetic material or other biomaterial can be freeze-dried according to the embodiments described herein.
  • a further embodiment of the present invention involves the use of the two component system described herein to stabilize proteins and other biomaterials against the detrimental effects of alternative means of drying, including spray drying or vacuum centrifugation.
  • EXAMPLE 1 Rabbit muscle lactate dehydrogenase (M isozyme, 99+% homogeneous) was purchased as a crystalline suspension in ammonium sulfate (Sigma; St. Louis, Mo) . Prior to each experiment the lactate dehydrogenase (“LDH”) was dialyzed (4°C) for several hours against 10 rriM potassium phosphate buffer (pH 7.5 at 23°C) . An aliquot of the stock enzyme was added to the appropriate preparation of polyethylene glycol (MW 8000) (prepared in the 10 mM potassium phosphate buffer) to a final LDH concentration of 25 g/ml and 10% (wt/vol) of polyethylene glycol (PEG) .
  • LDH lactate dehydrogenase
  • Samples of various concentrations of PEG were obtained by diluting the above mixture with a solution containing 25 ⁇ g/ml of LDH in the buffer alone.
  • 25 / -g/ml of LDH was prepared in the buffer containing 1% (wt/vol) PEG and 100 mM trehalose.
  • Various concentrations of trehalose were obtained by diluting this mixture with a buffer solution containing 25 /-g/ml LDH and 1% PEG without trehalose.
  • FREEZE-THA EXPERIMENTS A 75 ⁇ l aliquot of a given mixture was transferred to a 1.5 ml polypropylene Eppendorf test tube. A 10 ⁇ l sample was removed and assayed for LDH catalytic activity. This served as the pre-treatment control value. LDH catalytic activity was measured at 25°C.
  • the 2.0 ml reaction mixture contained 80 mM Tris/Hcl buffer (pH 7.5), 100 mM KC1, 2 mM pyruvate, and 0.15 mM NADH. The remaining 65 ⁇ l aliquot in the test tube was frozen by immersion into liquid nitrogen for 30 seconds. Samples were then thawed at room temperature, immediately mixed and assayed for residual activity. The results are expressed as the percentage of the pre- treatment activity recovered after thawing.
  • Fig. 1A demonstrate that PEG completely protects LDH from inactivation during freeze- thawing. Essentially full activity is recovered at all PEG concentrations tested. By contrast, PEG provides essentially no stabilization to the enzyme during freeze- drying. These results indicate that PEG is an ideal cryoprotectant for proteins, but that when used alone it does not have the capacity to stabilize freeze-dried proteins.
  • trehalose either alone or in combination with 1% PEG
  • Fig. IB The influence of trehalose (either alone or in combination with 1% PEG) on LDH stability during freeze- thawing is shown in Fig. IB.
  • the combination of trehalose and 1% PEG provides almost full protection for the enzyme during freeze-thawing.
  • trehalose alone provides almost no protection during freeze-thawing.
  • Fig. 1C shows the effect of trehalose alone and trehalose in combination with 1% PEG on the stability of LDH during freeze-drying.
  • Trehalose alone provides no stabilization and actually appears to cause additional damage to the enzyme during freeze-drying.
  • trehalose is used in combination with 1% PEG (which alone provides only minimal protection) almost 100% of the LDH activity is retained after freeze-drying.
  • PEG is the solute comprising component one, which fully protects against damage induced by freezing, while conferring minimal if any protection during the subsequent drying phase.
  • Trehalose is the solute comprising component two, which confers minimal protection during freezing, and when used alone affords no protection and/or is damaging during drying.
  • trehalose provides almost complete protection during the drying phase.
  • Fig. 2A The influence of lactose (either alone or in combination with 1% PEG) on LDH stability during freeze-thawing is shown in Fig. 2A.
  • the combination of lactose and 1% PEG provides protection for the enzyme during freeze-thawing.
  • lactose alone provides almost no protection during freeze-thawing.
  • Fig. 2B shows the effect of lactose alone and lactose in combination with 1% PEG on the stability of LDH during freeze-drying. Lactose alone provides no stabilization and appears to cause additional damage to the enzyme during freeze-drying.
  • lactose is used in combination with 1% PEG (which alone provides only minimal protection) the LDH is stabilized during freeze-drying.
  • Synergistic protection by the two components is realized during freeze-drying, with PEG providing stabilization against damage during freezing and lactose protecting during the drying phase.
  • EXAMPLE 3 Samples were prepared and treated as described in Example 1, except that glucose was substituted for trehalose and served as component two.
  • the influence of glucose (either alone or in combination with 1% PEG) on LDH stability during freeze-thawing is documented in Fig. 3A.
  • the combination of glucose and 1% PEG provides protection for the enzyme during freeze-thawing.
  • Fig. 3B shows the effects of glucose alone and glucose in combination with 1% PEG on the stability of LDH during freeze-drying.
  • Glucose alone provides no stabilization and actually appears to cause additional damage to the enzyme during freeze-drying.
  • glucose is used in combination with 1% PEG (which alone provide only minimal protection) the LDH is stabilized during freeze-drying.
  • Fig. 4A The influence of glycine (either alone or in combination with 1% PEG) on LDH stability during freeze-thawing is shown in Fig. 4A.
  • the combination of glycine and 1% PEG provides protection for the enzyme during freeze-thawing.
  • Fig. 4B shows the effects of glycine alone and in combination with 1% PEG on the stability of LDH during freeze-drying.
  • Glycine alone provides no stabilization and actually fosters additional damage to the enzyme during freeze-drying.
  • glycine is used in combination with 1% PEG (which alone provide only minimal protection) the LDH is greatly stabilized during freeze-drying.
  • Synergistic protection is realized during freeze-drying, with PEG providing stabilization against damage during freezing and glycine protection during the drying phase.
  • EXAMPLE 5 Samples were prepared and treated as described in Example 1. Mannitol was substituted for trehalose and served as component two. The influence of mannitol (either alone or in combination with 1% PEG) on LDH stability during freeze-thawing is shown in Fig. 5A. The combination of mannitol and 1% PEG provides protection for the enzyme during freeze-thawing. By contrast, mannitol alone provides almost no protection during freeze-thawing. Fig. 5B shows the effects of mannitol alone and in combination with 1% PEG on stability of LDH during freeze-drying. Mannitol alone provides no stabilization and actually fosters additional damage to the enzyme during freeze-drying. By contrast, when mannitol is used in combination with 1% PEG (which alone provide only minimal protection) the LDH is greatly stabilized during freeze-drying.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Procédé de stabilisation de biomatériaux au cours de la lyophilisation, à l'aide d'un additif à deux constituants. Un constituant agit comme un agent de protection cryogénique, tels que le polyéthylèneglycol, la polyvinylpyrrolidone, l'amidon hydroxyéthylique, le dextrane et le ficoll, qui protègent la protéine au cours de la congélation. Le second constituant, composé par exemple de sucres, d'alcools polyvalents, d'acides aminés ou de méthylamine, sert à protéger le biomatériau au cours de la déshydratation.
PCT/US1992/005643 1991-07-03 1992-07-02 Procede de stabilisation de biomateriaux WO1993000807A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72559391A 1991-07-03 1991-07-03
US725,593 1991-07-03

Publications (1)

Publication Number Publication Date
WO1993000807A1 true WO1993000807A1 (fr) 1993-01-21

Family

ID=24915184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/005643 WO1993000807A1 (fr) 1991-07-03 1992-07-02 Procede de stabilisation de biomateriaux

Country Status (2)

Country Link
AU (1) AU2309692A (fr)
WO (1) WO1993000807A1 (fr)

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013136A1 (fr) * 1992-12-04 1994-06-23 Development Biotechnological Processes S.N.C. Di Pelliccia Maria Teresa Solutions cryoprotectrices
BE1006379A3 (fr) * 1992-11-26 1994-08-09 Raymond Gilles Procede de conservation de cellules vivantes, d'ensembles de cellules et/ou de derives de ces cellules par lyophilisation.
US5424204A (en) * 1993-08-26 1995-06-13 Kyowa Medex Co., Ltd. Method for stabilizing glucose 6-phosphate dehydrogenase with hydroxylamines, aldehyde scavengers, dimethylthiocarbamoyl chloride or 2-(2-aminoethylamino) ethanol
DE19503685A1 (de) * 1995-01-30 1996-08-01 Invitek Gmbh Verfahren zur Herstellung komplexer multienzymatischer lagerstabiler Reaktionsgemische und deren Verwendung
EP0726310A1 (fr) * 1995-02-10 1996-08-14 Gen-Probe Incorporated Compositions d'enzyme stabilisées pour l'amplification d'acides nucléiques
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
WO1996041870A1 (fr) * 1995-06-08 1996-12-27 Societa' Cooperativa Centro Ricerche Poly-Tech A Responsabilita' Limitata Compositions hydrosolubles de collagenase et procede de preparation
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
WO1998000530A1 (fr) * 1996-07-03 1998-01-08 Molecular Biology Resources, Inc. Procede et formulation permettant la stabilisation d'enzymes
WO1998006421A1 (fr) * 1996-08-16 1998-02-19 Cancer Treatments International Compositions therapeutiques destinees au traitement du cancer
WO1998022136A2 (fr) 1996-11-19 1998-05-28 Roche Diagnostics Gmbh Preparations pharmaceutiques lyophilisees stables d'anticorps monoclonaux ou polyclonaux
US5879875A (en) * 1996-06-14 1999-03-09 Biostore New Zealand Compositions and methods for the preservation of living tissues
WO1999045966A1 (fr) * 1998-03-13 1999-09-16 American Home Products Corporation Composition polynucleotidique, procede de preparation et utilisation
US5962213A (en) * 1996-06-14 1999-10-05 Biostore New Zealand Limited Compositions and methods for the preservation of living tissues
US6007810A (en) * 1997-05-02 1999-12-28 Seikagaku Corporation Chondroitinase compositions
US6037116A (en) * 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
US6040132A (en) * 1996-06-14 2000-03-21 Biostore New Zealand, Ltd. Methods for the lyophilization of living biological materials
EP0997734A1 (fr) * 1998-10-29 2000-05-03 Council of Scientific and Industrial Research Composition utilisable pour le diagnostic précoce de la Leishmaniose viscérale et le procédé de sa préparation
US6060233A (en) * 1996-06-14 2000-05-09 Biostore New Zealand, Ltd Methods for the lyophilization of platelets, platelet membranes or erythrocytes
WO2000009086A3 (fr) * 1998-08-14 2000-06-08 Valentis Inc Formulation protegee, dans un seul flacon, pour molecules d'acide nucleique, ses procedes de fabrication par melangeage en ligne, produits et procedes associes
US6114107A (en) * 1996-06-14 2000-09-05 Biostore New Zealand Limited Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues
US6221385B1 (en) 1996-05-10 2001-04-24 Vrije Universiteit Brussel Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
EP0836645A4 (fr) * 1995-06-09 2001-11-21 Univ California Formulations en poudre seche a base de complexes polynucleotidiques
EP0833667A4 (fr) * 1995-06-07 2001-11-21 Univ California Stabilisation de complexes de polynucleotides
US6361933B1 (en) 1996-06-14 2002-03-26 Biostore New Zealand Limited Solutions for the preservation of tissues
US6423529B1 (en) 1997-12-08 2002-07-23 Council Of Scientific & Industrial Research Composition useful for the early diagnosis of visceral leishmaniasis and a process for preparing the same
US6440747B2 (en) * 1998-10-30 2002-08-27 Dade Behring Marburg Gmbh Stabilization of biological fluids by addition of sterol esters
WO2002072002A2 (fr) 2001-03-12 2002-09-19 Biotools Biotechnological & Medical Laboratories, S.A. Procede de preparation de melanges de reaction stabilises, totalement ou partiellement desseches, qui comprennent au moins une enzyme, melanges de reaction et trousses contenant lesdits melanges
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
WO2004000347A1 (fr) 2002-06-21 2003-12-31 Novo Nordisk A/S Compositions solides stabilisees de polypeptides de facteur vii
ES2214144A1 (es) * 2003-02-26 2004-09-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Composicion estabilizada para ensayos fluorimetricos, colorimetricos o quimio-luminiscentes, kits que la contienen y procedimiento para su obtencion.
EP0868916A3 (fr) * 1997-03-04 2004-09-15 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent-inhibiteur de la réduction pour l'activité d'élimination d'oxygène actif
JP2004256545A (ja) * 2000-02-08 2004-09-16 Allergan Inc ボツリヌス毒素医薬組成物
EP1455822A4 (fr) * 2001-11-09 2004-12-29 Centocor Inc Compositions lyophilisees d'anticorps monoclonaux
EP1555033A3 (fr) * 1998-03-13 2005-08-17 Wyeth Composition polynucléotidique, procédé de préparation et utilisation
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
WO2006071373A1 (fr) * 2004-12-23 2006-07-06 Aurx, Inc. A Maryland Corporation Stabilisation de préparations virales
WO2006023665A3 (fr) * 2004-08-17 2006-08-03 Regeneron Pharma Formulations d'un antagoniste il-1
US7087723B2 (en) 1999-02-22 2006-08-08 Baxter International Inc. Albumin-free factor VIII formulations
JP2007507422A (ja) * 2003-07-14 2007-03-29 ナンニン メイプル リーフ ファーマシューティカル カンパニー リミテッド テトロドトキシンの安定な凍結乾燥医薬製剤
US7276359B1 (en) 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
EP1663292A4 (fr) * 2003-08-06 2007-11-21 Cj Corp Formulation d'erythropoietine ne contenant pas d'albumine
US7323297B1 (en) * 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
US7338810B2 (en) * 2002-06-18 2008-03-04 Canon Kabushiki Kaisha Substrate processing method and method for manufacturing probe carrier
EP1974723A2 (fr) 2003-11-29 2008-10-01 Merck Patent GmbH Formes solides d'anticorps anti-EGFR
WO2008101179A3 (fr) * 2007-02-16 2008-12-24 Wyeth Corp Utilisation de saccharose pour supprimer une agrégation de protéines provoquée par du mannitol
WO2008155529A1 (fr) * 2007-06-16 2008-12-24 Enigma Diagnostics Limited Compositions
WO2008090340A3 (fr) * 2007-01-23 2009-01-08 Diagnostics For The Real World Amplification et test d'acide nucléique
US7572893B2 (en) 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7790852B2 (en) 2003-06-25 2010-09-07 Novo Nordisk Health Care A/G Liquid composition of factor VII polypeptides
JP2010213699A (ja) * 1998-11-06 2010-09-30 Sterrenbeld Biotechnologie North America Inc 組換えヒトエリスロポイエチンを発現する宿主細胞
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2011048227A1 (fr) 2009-10-22 2011-04-28 Biotools Biotechnological & Medical Laboratories, S.A. Composition, méthode et trousse pour la détection de bactéries par séquençage
US8022031B2 (en) 2001-12-21 2011-09-20 Novo Nordisk Health Care A/G Liquid composition of factor VII polypeptides
US8026214B2 (en) 2003-08-14 2011-09-27 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
US20130059380A1 (en) * 2010-02-17 2013-03-07 Hememics Biotechnologies, Inc. Preservation solutions for biologics and methods related thereto
US8404638B2 (en) 2005-03-25 2013-03-26 Regeneron Pharmaceuticals, Inc. Dimer VEGF antagonist formulations
US20130129685A1 (en) * 2010-03-31 2013-05-23 Stabilitech Ltd. Stabilisation of Viral Particles
JP2013527832A (ja) * 2010-03-22 2013-07-04 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化に有用な組成物及び方法
WO2013112897A1 (fr) * 2012-01-27 2013-08-01 The Regents Of The University Of California Stabilisation de biomolécules au moyen de polymères de glucides
US8536127B2 (en) 2003-05-23 2013-09-17 Novo Nordisk Healthcare Ag Protein stabilization in solution
US8795669B2 (en) 2011-07-28 2014-08-05 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
JP2015500029A (ja) * 2011-12-09 2015-01-05 テゴ サイエンス インコーポレイテッド 細胞の有用物質を常温で安定して保存する方法
US9283273B2 (en) 1995-07-27 2016-03-15 Genentech, Inc. Protein formulation
US9402898B2 (en) 2012-01-23 2016-08-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
US9550837B2 (en) 2008-12-15 2017-01-24 Regeneron Pharmaceuticals, Inc. Therapeutic uses of anti-PCSK9 antibodies
US9561155B2 (en) 2011-01-28 2017-02-07 Sanofi Biotechnology Method of reducing cholesterol levels using a human anti-PCSK9 antibody
US9642353B2 (en) 2007-09-24 2017-05-09 Hememics Biotechnologies, Inc. Desiccated biologics and methods of preparing the same
US9675692B2 (en) 2012-05-31 2017-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-DLL4 antibodies
CZ306818B6 (cs) * 2015-01-29 2017-07-26 Masarykova Univerzita Způsob potlačení mrazové denaturace bílkovin při mrazení a/nebo lyofilizaci biologicky aktivních látek
US9724411B2 (en) 2008-12-15 2017-08-08 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9
US9738923B2 (en) 2014-06-18 2017-08-22 Luminex Corporation Methods for generating stabilized lyophilized materials
US10029007B2 (en) 2011-10-05 2018-07-24 Stabilitech Biopharma Ltd Stabilisation of polypeptides
US10076571B2 (en) 2011-09-16 2018-09-18 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US10512674B2 (en) 2008-11-07 2019-12-24 Baxalta Incorporated Factor VIII formulations
CN110699346A (zh) * 2019-11-13 2020-01-17 河北省微生物研究所 葡萄糖氧化酶冻干粉的制备方法
US10544232B2 (en) 2014-07-16 2020-01-28 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US10716859B2 (en) 2010-03-31 2020-07-21 Stabilitech Biopharma Ltd Excipients for stabilising viral particles, polypeptides or biological material
US10765552B2 (en) 2016-02-18 2020-09-08 Zeltiq Aesthetics, Inc. Cooling cup applicators with contoured heads and liner assemblies
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US10806500B2 (en) 2014-01-31 2020-10-20 Zeltiq Aesthetics, Inc. Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments
US10806783B2 (en) 2014-04-11 2020-10-20 Stabilitech Biopharma Ltd Vaccine compositions
US10980871B2 (en) 2017-05-08 2021-04-20 Iosbio Ltd Vaccine compositions
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)
US11076879B2 (en) 2017-04-26 2021-08-03 Zeltiq Aesthetics, Inc. Shallow surface cryotherapy applicators and related technology
US11154418B2 (en) 2015-10-19 2021-10-26 Zeltiq Aesthetics, Inc. Vascular treatment systems, cooling devices, and methods for cooling vascular structures
US11179269B2 (en) 2006-09-26 2021-11-23 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US11395760B2 (en) 2006-09-26 2022-07-26 Zeltiq Aesthetics, Inc. Tissue treatment methods
US11446175B2 (en) 2018-07-31 2022-09-20 Zeltiq Aesthetics, Inc. Methods, devices, and systems for improving skin characteristics
US11452634B2 (en) 2009-04-30 2022-09-27 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US11583438B1 (en) 2007-08-21 2023-02-21 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US11732024B2 (en) 2006-06-16 2023-08-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
CN117705541A (zh) * 2024-02-05 2024-03-15 江西赛基生物技术有限公司 用于血样pd-1检测的质控品及其制备与质控方法
US11986421B2 (en) 2006-09-26 2024-05-21 Zeltiq Aesthetics, Inc. Cooling devices with flexible sensors
US12070411B2 (en) 2006-04-28 2024-08-27 Zeltiq Aesthetics, Inc. Cryoprotectant for use with a treatment device for improved cooling of subcutaneous lipid-rich cells
WO2025105548A1 (fr) * 2023-11-15 2025-05-22 ㈜바이오제닉스 Composition de complexe stabilisante pour maintenir l'activité d'une protéine et son procédé de préparation
US12414558B2 (en) 2014-11-14 2025-09-16 Japanese Red Cross Society Method for administering umbilical cord blood or peripheral blood

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177117A (en) * 1961-12-26 1965-04-06 Joseph F Saunders Process for freezing blood
US4439421A (en) * 1982-08-30 1984-03-27 Baxter Travenol Laboratories, Inc. Stabilized gamma globulin concentrate
US4574081A (en) * 1984-09-25 1986-03-04 Colgate-Palmolive Co. Antiplaque dentifrice having improved flavor
US4874690A (en) * 1988-08-26 1989-10-17 Cryopharm Corporation Lyophilization of red blood cells
WO1989009610A1 (fr) * 1988-04-13 1989-10-19 Cetus Corporation Formulations de facteur de necrose tumorale
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177117A (en) * 1961-12-26 1965-04-06 Joseph F Saunders Process for freezing blood
US4439421A (en) * 1982-08-30 1984-03-27 Baxter Travenol Laboratories, Inc. Stabilized gamma globulin concentrate
US4574081A (en) * 1984-09-25 1986-03-04 Colgate-Palmolive Co. Antiplaque dentifrice having improved flavor
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
WO1989009610A1 (fr) * 1988-04-13 1989-10-19 Cetus Corporation Formulations de facteur de necrose tumorale
US4874690A (en) * 1988-08-26 1989-10-17 Cryopharm Corporation Lyophilization of red blood cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL DIARY SCIENCE, Volume 73, Number 12, 1-33, issued 1990, CARPENTER et al., "Comparison of Solute-Induced Protein Stabilization in Aqueous Solution and in the Frozen and Dried States", pages 3627-36. *
TRANSPLANTATION, Volume 49, Number 2, issued February 1990, W. WICOMB et al., "Optimal Cardioplegia and 24-Hour Heart Storage with Simplified UW Solution Containing Polyethylene Glycol", pages 261-264. *

Cited By (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
US7323297B1 (en) * 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
BE1006379A3 (fr) * 1992-11-26 1994-08-09 Raymond Gilles Procede de conservation de cellules vivantes, d'ensembles de cellules et/ou de derives de ces cellules par lyophilisation.
WO1994013135A1 (fr) * 1992-12-04 1994-06-23 Development Biotechnological Processes S.N.C. Di Pelliccia Maria Teresa SOLUTIONS AQUEUSES CRYOPROTECTRICES UTILES POUR LA CONSERVATION DE FEUILLES D'EPITHELIUM OBTENUES PAR CULTURE $i(IN VITRO)
WO1994013136A1 (fr) * 1992-12-04 1994-06-23 Development Biotechnological Processes S.N.C. Di Pelliccia Maria Teresa Solutions cryoprotectrices
US5670308A (en) * 1992-12-04 1997-09-23 Development Biotechnological Processes Snc Di Pelliccia Maria Teresa Cryoprotective aqueous solutions useful for the preservation of in vitro cultured epithelial sheets
US5424204A (en) * 1993-08-26 1995-06-13 Kyowa Medex Co., Ltd. Method for stabilizing glucose 6-phosphate dehydrogenase with hydroxylamines, aldehyde scavengers, dimethylthiocarbamoyl chloride or 2-(2-aminoethylamino) ethanol
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
DE19503685A1 (de) * 1995-01-30 1996-08-01 Invitek Gmbh Verfahren zur Herstellung komplexer multienzymatischer lagerstabiler Reaktionsgemische und deren Verwendung
DE19503685C2 (de) * 1995-01-30 2000-05-31 Invitek Gmbh Verfahren zur Herstellung komplexer multienzymatischer lagerstabiler Reaktionsgemische und deren Verwendung
US5614387A (en) * 1995-02-10 1997-03-25 Gen-Probe Incorporated Method of making stabilized enzyme compositions for nucleic acid amplification
WO1996024664A1 (fr) * 1995-02-10 1996-08-15 Gen-Probe Incorporated Compositions d'enzymes stabilisees pour amplification d'acide nucleique
EP0726310A1 (fr) * 1995-02-10 1996-08-14 Gen-Probe Incorporated Compositions d'enzyme stabilisées pour l'amplification d'acides nucléiques
US5834254A (en) * 1995-02-10 1998-11-10 Gen-Probe Incorporated Stabilized enzyme compositions for nucleic acid amplification
AU699590B2 (en) * 1995-02-10 1998-12-10 Gen-Probe Incorporated Stabilized enzyme compositions for nucleic acid amplification
EP1491217A1 (fr) * 1995-06-07 2004-12-29 The Regents Of The University Of California Stabilisation de complexes de polynucléotides
EP0833667A4 (fr) * 1995-06-07 2001-11-21 Univ California Stabilisation de complexes de polynucleotides
WO1996041870A1 (fr) * 1995-06-08 1996-12-27 Societa' Cooperativa Centro Ricerche Poly-Tech A Responsabilita' Limitata Compositions hydrosolubles de collagenase et procede de preparation
EP0836645A4 (fr) * 1995-06-09 2001-11-21 Univ California Formulations en poudre seche a base de complexes polynucleotidiques
US9283273B2 (en) 1995-07-27 2016-03-15 Genentech, Inc. Protein formulation
US6221385B1 (en) 1996-05-10 2001-04-24 Vrije Universiteit Brussel Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
US6114107A (en) * 1996-06-14 2000-09-05 Biostore New Zealand Limited Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues
US6037116A (en) * 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
US6040132A (en) * 1996-06-14 2000-03-21 Biostore New Zealand, Ltd. Methods for the lyophilization of living biological materials
US6060233A (en) * 1996-06-14 2000-05-09 Biostore New Zealand, Ltd Methods for the lyophilization of platelets, platelet membranes or erythrocytes
US5879875A (en) * 1996-06-14 1999-03-09 Biostore New Zealand Compositions and methods for the preservation of living tissues
US6361933B1 (en) 1996-06-14 2002-03-26 Biostore New Zealand Limited Solutions for the preservation of tissues
US5962213A (en) * 1996-06-14 1999-10-05 Biostore New Zealand Limited Compositions and methods for the preservation of living tissues
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
WO1998000530A1 (fr) * 1996-07-03 1998-01-08 Molecular Biology Resources, Inc. Procede et formulation permettant la stabilisation d'enzymes
US6294365B1 (en) 1996-07-03 2001-09-25 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
WO1998006421A1 (fr) * 1996-08-16 1998-02-19 Cancer Treatments International Compositions therapeutiques destinees au traitement du cancer
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
WO1998022136A2 (fr) 1996-11-19 1998-05-28 Roche Diagnostics Gmbh Preparations pharmaceutiques lyophilisees stables d'anticorps monoclonaux ou polyclonaux
US7186824B2 (en) 1997-03-04 2007-03-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Reduction inhibitory agent for active-oxygen eliminating activity
EP0868916A3 (fr) * 1997-03-04 2004-09-15 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent-inhibiteur de la réduction pour l'activité d'élimination d'oxygène actif
US6007810A (en) * 1997-05-02 1999-12-28 Seikagaku Corporation Chondroitinase compositions
EP0875253A3 (fr) * 1997-05-02 2000-11-22 Seikagaku Corporation Compositionsde chondroitinase
US6423529B1 (en) 1997-12-08 2002-07-23 Council Of Scientific & Industrial Research Composition useful for the early diagnosis of visceral leishmaniasis and a process for preparing the same
US7276359B1 (en) 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
EP1555033A3 (fr) * 1998-03-13 2005-08-17 Wyeth Composition polynucléotidique, procédé de préparation et utilisation
WO1999045966A1 (fr) * 1998-03-13 1999-09-16 American Home Products Corporation Composition polynucleotidique, procede de preparation et utilisation
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6534483B1 (en) 1998-08-14 2003-03-18 Valentis, Inc. Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
WO2000009086A3 (fr) * 1998-08-14 2000-06-08 Valentis Inc Formulation protegee, dans un seul flacon, pour molecules d'acide nucleique, ses procedes de fabrication par melangeage en ligne, produits et procedes associes
EP0997734A1 (fr) * 1998-10-29 2000-05-03 Council of Scientific and Industrial Research Composition utilisable pour le diagnostic précoce de la Leishmaniose viscérale et le procédé de sa préparation
US6440747B2 (en) * 1998-10-30 2002-08-27 Dade Behring Marburg Gmbh Stabilization of biological fluids by addition of sterol esters
JP2010213699A (ja) * 1998-11-06 2010-09-30 Sterrenbeld Biotechnologie North America Inc 組換えヒトエリスロポイエチンを発現する宿主細胞
US9352027B2 (en) 1999-02-22 2016-05-31 Baxalta Incorporated Albumin-free factor VIII formulations
US7087723B2 (en) 1999-02-22 2006-08-08 Baxter International Inc. Albumin-free factor VIII formulations
US7247707B2 (en) 1999-02-22 2007-07-24 Baxter International Inc. Albumin-free factor VIII formulations
US9669076B2 (en) 1999-02-22 2017-06-06 Baxalta Incorporated Albumin-free factor VIII formulations
US8372800B2 (en) 1999-02-22 2013-02-12 Baxter International Inc. Albumin-free factor VIII formulations
US8765665B2 (en) 1999-02-22 2014-07-01 Baxter International Inc. Albumin-free factor VIII formulations
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
JP2004256545A (ja) * 2000-02-08 2004-09-16 Allergan Inc ボツリヌス毒素医薬組成物
WO2002072002A3 (fr) * 2001-03-12 2002-11-28 Biotools Biotechnological & Me Procede de preparation de melanges de reaction stabilises, totalement ou partiellement desseches, qui comprennent au moins une enzyme, melanges de reaction et trousses contenant lesdits melanges
JP2004519242A (ja) * 2001-03-12 2004-07-02 ビオトールズ ビオテクノロジカル アンド メディカル ラボラトリーズ，エス．エー． 完全にまたは部分的に乾燥した１つ以上の酵素を含む安定化反応混合物の製造方法、および該反応混合物並びにこれを含有するキット
ES2180416A1 (es) * 2001-03-12 2003-02-01 Biotools Biotechnological & Me Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
US7919294B2 (en) 2001-03-12 2011-04-05 Biotools Biotechnological & Medical Laboratories, S.A. Process for preparing stabilized reaction mixtures which are partially dried, comprising at least one enzyme, reaction mixtures and kits containing said mixtures
WO2002072002A2 (fr) 2001-03-12 2002-09-19 Biotools Biotechnological & Medical Laboratories, S.A. Procede de preparation de melanges de reaction stabilises, totalement ou partiellement desseches, qui comprennent au moins une enzyme, melanges de reaction et trousses contenant lesdits melanges
AU2002246125B2 (en) * 2001-03-12 2008-02-07 Biotools Biotechnological & Medical Laboratories, S.A. Process for preparing stabilized reaction mixtures which are partially dried, comprising at least one enzyme, reaction mixtures and kits containing said mixtures
EP1455822A4 (fr) * 2001-11-09 2004-12-29 Centocor Inc Compositions lyophilisees d'anticorps monoclonaux
US8461116B2 (en) 2001-12-21 2013-06-11 Novo Nordisk Healthcare Ag Liquid composition of factor VII polypeptides
US8022031B2 (en) 2001-12-21 2011-09-20 Novo Nordisk Health Care A/G Liquid composition of factor VII polypeptides
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US7449444B2 (en) 2002-03-15 2008-11-11 Wyeth Hydroxyethyl starch-containing polypeptide compositions
US7338810B2 (en) * 2002-06-18 2008-03-04 Canon Kabushiki Kaisha Substrate processing method and method for manufacturing probe carrier
JP2006513983A (ja) * 2002-06-21 2006-04-27 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの安定化された固体組成物
EP2283856A1 (fr) * 2002-06-21 2011-02-16 Novo Nordisk Health Care AG Compositions solides stabilisé de facteur vii polypeptides
WO2004000347A1 (fr) 2002-06-21 2003-12-31 Novo Nordisk A/S Compositions solides stabilisees de polypeptides de facteur vii
US8729022B2 (en) 2002-06-21 2014-05-20 Novo Nordisk Healthcare Ag Stabilised solid compositions of factor VII polypeptides
US8299029B2 (en) 2002-06-21 2012-10-30 Novo Nordisk Health Care Ag Stabilised solid compositions of factor VII polypeptides
ES2214144A1 (es) * 2003-02-26 2004-09-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Composicion estabilizada para ensayos fluorimetricos, colorimetricos o quimio-luminiscentes, kits que la contienen y procedimiento para su obtencion.
WO2004076656A1 (fr) * 2003-02-26 2004-09-10 Biotools Biotechnological & Medical Laboratories, S.A. Composition stabilisee pour essais fluorimetriques, colorimetriques ou chimioluminescents, kits contenant ladite composition et procede d'obtention
ES2214144B1 (es) * 2003-02-26 2005-09-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Composicion estabilizada para ensayos fluorimetricos, colorimetricos o quimio-luminiscentes, kits que la contienen y procedimiento para su obtencion.
US8084587B2 (en) 2003-03-26 2011-12-27 Novo Nordisk Health Care Ag Method for the production of proteins
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US8536127B2 (en) 2003-05-23 2013-09-17 Novo Nordisk Healthcare Ag Protein stabilization in solution
US7790852B2 (en) 2003-06-25 2010-09-07 Novo Nordisk Health Care A/G Liquid composition of factor VII polypeptides
US8222258B2 (en) 2003-07-14 2012-07-17 Wex Medical Limited Stable pharmaceutical composition of freeze-dried tetrodoxin powder
US8124608B2 (en) * 2003-07-14 2012-02-28 Wex Medical Limited Stable pharmaceutical composition of freeze-dried tetrodotoxin powder
US8530481B2 (en) 2003-07-14 2013-09-10 Wex Medical Limited Stable pharmaceutical composition of freeze-dried tetrodotoxin powder
JP2007507422A (ja) * 2003-07-14 2007-03-29 ナンニン メイプル リーフ ファーマシューティカル カンパニー リミテッド テトロドトキシンの安定な凍結乾燥医薬製剤
EP1663292A4 (fr) * 2003-08-06 2007-11-21 Cj Corp Formulation d'erythropoietine ne contenant pas d'albumine
US8026214B2 (en) 2003-08-14 2011-09-27 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
US8318904B2 (en) 2003-08-14 2012-11-27 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
EP1974723A2 (fr) 2003-11-29 2008-10-01 Merck Patent GmbH Formes solides d'anticorps anti-EGFR
WO2006023665A3 (fr) * 2004-08-17 2006-08-03 Regeneron Pharma Formulations d'un antagoniste il-1
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
JP2008510716A (ja) * 2004-08-17 2008-04-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−１アンタゴニスト製剤
US7572893B2 (en) 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US7365165B2 (en) 2004-08-17 2008-04-29 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
AU2005277357B2 (en) * 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
WO2006071373A1 (fr) * 2004-12-23 2006-07-06 Aurx, Inc. A Maryland Corporation Stabilisation de préparations virales
US9416167B2 (en) 2005-03-25 2016-08-16 Regeneron Pharmaceuticals, Inc. Stable liquid formulations of dimer VEGF antagonists
US8921316B2 (en) 2005-03-25 2014-12-30 Regeneron Pharmaceuticals, Inc. Stable liquid VEGF antagonist formulations
US9511140B2 (en) 2005-03-25 2016-12-06 Regeneron Pharmaceuticals, Inc. Stable VEGF antagonist formulations
US11806398B2 (en) 2005-03-25 2023-11-07 Regeneron Pharmaceuticals, Inc. Citrate buffered VEGF antagonist formulations
US8404638B2 (en) 2005-03-25 2013-03-26 Regeneron Pharmaceuticals, Inc. Dimer VEGF antagonist formulations
US8710004B2 (en) 2005-03-25 2014-04-29 Regeneron Pharmaceuticals, Inc. Stable liquid VEGF antagonist formulations
US9636400B2 (en) 2005-03-25 2017-05-02 Regeneron Pharmaceuticals, Inc. VEGF specific fusion protein antagonist formulations
US10406226B2 (en) 2005-03-25 2019-09-10 Regeneron Pharmaceuticals, Inc. Method of manufacturing VEGF antagonist fusion proteins
US10857231B2 (en) 2005-03-25 2020-12-08 Regeneron Pharmaceuticals, Inc. Formulations of VEG antagonist fusion proteins and method of manufacturing them
US12070411B2 (en) 2006-04-28 2024-08-27 Zeltiq Aesthetics, Inc. Cryoprotectant for use with a treatment device for improved cooling of subcutaneous lipid-rich cells
US11732024B2 (en) 2006-06-16 2023-08-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US12331099B2 (en) 2006-06-16 2025-06-17 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US11986421B2 (en) 2006-09-26 2024-05-21 Zeltiq Aesthetics, Inc. Cooling devices with flexible sensors
US11219549B2 (en) 2006-09-26 2022-01-11 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US11395760B2 (en) 2006-09-26 2022-07-26 Zeltiq Aesthetics, Inc. Tissue treatment methods
US11179269B2 (en) 2006-09-26 2021-11-23 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
EP2527470A3 (fr) * 2007-01-23 2012-12-05 Cambridge Enterprise Limited Amplification d'acide nucléique et test
US11447821B2 (en) 2007-01-23 2022-09-20 Cambridge Enterprise Limited Nucleic acid amplification and testing
WO2008090340A3 (fr) * 2007-01-23 2009-01-08 Diagnostics For The Real World Amplification et test d'acide nucléique
US10563254B2 (en) 2007-01-23 2020-02-18 Cambridge Enterprise Limited Nucleic acid amplification and testing
WO2008101179A3 (fr) * 2007-02-16 2008-12-24 Wyeth Corp Utilisation de saccharose pour supprimer une agrégation de protéines provoquée par du mannitol
WO2008155529A1 (fr) * 2007-06-16 2008-12-24 Enigma Diagnostics Limited Compositions
US11583438B1 (en) 2007-08-21 2023-02-21 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US9642353B2 (en) 2007-09-24 2017-05-09 Hememics Biotechnologies, Inc. Desiccated biologics and methods of preparing the same
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
US10512674B2 (en) 2008-11-07 2019-12-24 Baxalta Incorporated Factor VIII formulations
US11020459B2 (en) 2008-11-07 2021-06-01 Baxalta Incorporated Factor VIII formulations
US12269897B2 (en) 2008-12-15 2025-04-08 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
US9724411B2 (en) 2008-12-15 2017-08-08 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9
US10941210B2 (en) 2008-12-15 2021-03-09 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
US10023654B2 (en) 2008-12-15 2018-07-17 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
US9550837B2 (en) 2008-12-15 2017-01-24 Regeneron Pharmaceuticals, Inc. Therapeutic uses of anti-PCSK9 antibodies
US11452634B2 (en) 2009-04-30 2022-09-27 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
WO2011048227A1 (fr) 2009-10-22 2011-04-28 Biotools Biotechnological & Medical Laboratories, S.A. Composition, méthode et trousse pour la détection de bactéries par séquençage
US9943075B2 (en) * 2010-02-17 2018-04-17 Hememics Biotechnologies, Inc. Preservation solutions for biologics and methods related thereto
US20130059380A1 (en) * 2010-02-17 2013-03-07 Hememics Biotechnologies, Inc. Preservation solutions for biologics and methods related thereto
EP3513810A1 (fr) * 2010-03-22 2019-07-24 F. Hoffmann-La Roche AG Compositions et procédés utiles pour stabiliser des formulations contenant des protéines
US9662395B2 (en) 2010-03-22 2017-05-30 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
JP2013527832A (ja) * 2010-03-22 2013-07-04 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化に有用な組成物及び方法
JP2016193909A (ja) * 2010-03-22 2016-11-17 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化に有用な組成物及び方法
US10206960B2 (en) * 2010-03-31 2019-02-19 Stabilitech Biopharma Ltd Stabilisation of viral particles
US20130129685A1 (en) * 2010-03-31 2013-05-23 Stabilitech Ltd. Stabilisation of Viral Particles
US10716859B2 (en) 2010-03-31 2020-07-21 Stabilitech Biopharma Ltd Excipients for stabilising viral particles, polypeptides or biological material
US9682013B2 (en) 2011-01-28 2017-06-20 Sanofi Biotechnology Pharmaceutical compositions comprising human antibodies to PCSK9
US12083176B2 (en) 2011-01-28 2024-09-10 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US11246925B2 (en) 2011-01-28 2022-02-15 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US9561155B2 (en) 2011-01-28 2017-02-07 Sanofi Biotechnology Method of reducing cholesterol levels using a human anti-PCSK9 antibody
US11033606B2 (en) 2011-04-26 2021-06-15 Sanofi Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)
US9193801B2 (en) 2011-07-28 2015-11-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US8795669B2 (en) 2011-07-28 2014-08-05 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US10752701B2 (en) 2011-07-28 2020-08-25 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US11673967B2 (en) 2011-07-28 2023-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US10472425B2 (en) 2011-07-28 2019-11-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US11116839B2 (en) 2011-09-16 2021-09-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10076571B2 (en) 2011-09-16 2018-09-18 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10029007B2 (en) 2011-10-05 2018-07-24 Stabilitech Biopharma Ltd Stabilisation of polypeptides
JP2015500029A (ja) * 2011-12-09 2015-01-05 テゴ サイエンス インコーポレイテッド 細胞の有用物質を常温で安定して保存する方法
US9402898B2 (en) 2012-01-23 2016-08-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
US10543280B2 (en) 2012-01-27 2020-01-28 The Regents Of The University Of California Stabilization of biomolecules using sugar polymers
WO2013112897A1 (fr) * 2012-01-27 2013-08-01 The Regents Of The University Of California Stabilisation de biomolécules au moyen de polymères de glucides
US9901648B2 (en) 2012-01-27 2018-02-27 The Regents Of The University Of California Stabilization of biomolecules using sugar polymers
US9675692B2 (en) 2012-05-31 2017-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-DLL4 antibodies
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10995150B2 (en) 2013-06-07 2021-05-04 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US10912599B2 (en) 2014-01-31 2021-02-09 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
US10806500B2 (en) 2014-01-31 2020-10-20 Zeltiq Aesthetics, Inc. Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments
US11819257B2 (en) 2014-01-31 2023-11-21 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
US10806783B2 (en) 2014-04-11 2020-10-20 Stabilitech Biopharma Ltd Vaccine compositions
US11098344B2 (en) 2014-06-18 2021-08-24 Luminex Corporation Methods for generating stabilized lyophilized materials
US9738923B2 (en) 2014-06-18 2017-08-22 Luminex Corporation Methods for generating stabilized lyophilized materials
US10144954B2 (en) 2014-06-18 2018-12-04 Luminex Corporation Methods for generating stabilized lyophilized materials
US10544232B2 (en) 2014-07-16 2020-01-28 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US11306155B2 (en) 2014-07-16 2022-04-19 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US11208461B2 (en) 2014-07-18 2021-12-28 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
US10501523B2 (en) 2014-07-18 2019-12-10 Sanofi IL-8 level based method of predicting the outcome of colon cancer treatment
US12414558B2 (en) 2014-11-14 2025-09-16 Japanese Red Cross Society Method for administering umbilical cord blood or peripheral blood
CZ306818B6 (cs) * 2015-01-29 2017-07-26 Masarykova Univerzita Způsob potlačení mrazové denaturace bílkovin při mrazení a/nebo lyofilizaci biologicky aktivních látek
US11904017B2 (en) 2015-08-18 2024-02-20 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US11154418B2 (en) 2015-10-19 2021-10-26 Zeltiq Aesthetics, Inc. Vascular treatment systems, cooling devices, and methods for cooling vascular structures
US10765552B2 (en) 2016-02-18 2020-09-08 Zeltiq Aesthetics, Inc. Cooling cup applicators with contoured heads and liner assemblies
US11076879B2 (en) 2017-04-26 2021-08-03 Zeltiq Aesthetics, Inc. Shallow surface cryotherapy applicators and related technology
US10980871B2 (en) 2017-05-08 2021-04-20 Iosbio Ltd Vaccine compositions
US12102557B2 (en) 2018-07-31 2024-10-01 Zeltiq Aesthetics, Inc. Methods, devices, and systems for improving skin characteristics
US11446175B2 (en) 2018-07-31 2022-09-20 Zeltiq Aesthetics, Inc. Methods, devices, and systems for improving skin characteristics
CN110699346A (zh) * 2019-11-13 2020-01-17 河北省微生物研究所 葡萄糖氧化酶冻干粉的制备方法
WO2025105548A1 (fr) * 2023-11-15 2025-05-22 ㈜바이오제닉스 Composition de complexe stabilisante pour maintenir l'activité d'une protéine et son procédé de préparation
CN117705541A (zh) * 2024-02-05 2024-03-15 江西赛基生物技术有限公司 用于血样pd-1检测的质控品及其制备与质控方法
CN117705541B (zh) * 2024-02-05 2024-04-26 江西赛基生物技术有限公司 用于血样pd-1检测的质控品及其制备与质控方法

Also Published As

Publication number Publication date
AU2309692A (en) 1993-02-11

Similar Documents

Publication Publication Date Title
WO1993000807A1 (fr) Procede de stabilisation de biomateriaux
AU2001268057B2 (en) Preservation and storage medium for biological materials
US6890512B2 (en) Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
US5792643A (en) Methods for preserving recombinant retroviruses
Lee Spray-drying of proteins
Carpenter et al. Modes of stabilization of a protein by organic solutes during desiccation
EP0871476B1 (fr) Composition de facteur sanguin deshydrate comprenant du trehalose
AU2009200127B2 (en) Preservation of bioactive materials by freeze dried foam
EP1374827B1 (fr) Procede de preparation de melanges de reaction stabilises, totalement ou partiellement desseches, qui comprennent au moins une enzyme, melanges de reaction et trousses contenant lesdits melanges
AU732274B2 (en) Methods and compositions for producing dried, storage-stable platelets
AU622978B2 (en) Storage of materials as solution in glassy, amorphous composition containing hydrophilic carrier
AU650678B2 (en) Stabilization (using gelatin from a cold water fish) of enzymes in diagnostic controls
US20030022333A1 (en) Long-term shelf preservation by vitrification
AU2001268057A1 (en) Preservation and storage medium for biological materials
CA2576519C (fr) Formulations d'un antagoniste il-1
Sampedro et al. Trehalose-Mediated Protection of the Plasma Membrane H+-ATPase fromKluyveromyces lactisduring Freeze-Drying and Rehydration
CN112485451B (zh) 一种白介素6冻干校准品及其制备方法与冻干保护液
US20010046487A1 (en) Methods for loading platelets, stabilizing platelets for dry storage and compositions obtained thereby
Gibson et al. The stabilisation of analytical enzymes using polyelectrolytes and sugar derivatives
WO1994024273A1 (fr) Compositions stables a base de collagenase et procedes de preparation
Boudrant et al. Continuous proteolysis with a stabilized protease. I. Chemical stabilization of an alkaline protease
JPS6322161B2 (fr)
Nelson et al. Growth inhibitory and arginase activities in liver and hepatoma extracts
RU2061755C1 (ru) СПОСОБ СТАБИЛИЗАЦИИ УЛЬТРАКОНЦЕНТРАТА ГРИБНОЙ β -ГАЛАКТОЗИДАЗЫ
CA2254431A1 (fr) Prevention de l'agregation irreversible de microorganismes viables au sechage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1992914862

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992914862

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase